Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Inflammatory Bowel Diseases

  Free Subscription


08.05.2017

1 Aliment Pharmacol Ther
1 Clin Exp Immunol
1 Dig Dis Sci
4 Eur J Gastroenterol Hepatol
1 Gastroenterology
1 Inflamm Bowel Dis
1 J Clin Gastroenterol
13 J Crohns Colitis
1 J Immunol
2 N Engl J Med
1 Scand J Gastroenterol


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Aliment Pharmacol Ther

  1. NORTON C, Czuber-Dochan W, Artom M, Sweeney L, et al
    Systematic review: interventions for abdominal pain management in inflammatory bowel disease.
    Aliment Pharmacol Ther. 2017 May 4. doi: 10.1111/apt.14108.
    PubMed     Text format     Abstract available


    Clin Exp Immunol

  2. KOOIJ IA, Sahami S, Meijer SL, Buskens CJ, et al
    The immunology of the vermiform appendix: a review of the literature.
    Clin Exp Immunol. 2016;186:1-9.
    PubMed     Text format     Abstract available


    Dig Dis Sci

  3. MEIGHANI A, Hart BR, Bourgi K, Miller N, et al
    Outcomes of Fecal Microbiota Transplantation for Clostridium difficile Infection in Patients with Inflammatory Bowel Disease.
    Dig Dis Sci. 2017 Apr 27. doi: 10.1007/s10620-017-4580.
    PubMed     Text format     Abstract available


    Eur J Gastroenterol Hepatol

  4. BAHLER C, Schoepfer AM, Vavricka SR, Brungger B, et al
    Chronic comorbidities associated with inflammatory bowel disease: prevalence and impact on healthcare costs in Switzerland.
    Eur J Gastroenterol Hepatol. 2017 May 3. doi: 10.1097/MEG.0000000000000891.
    PubMed     Text format     Abstract available

  5. WARDLE RA, Wardle AJ, Charadva C, Ghosh S, et al
    Literature review: impacts of socioeconomic status on the risk of inflammatory bowel disease and its outcomes.
    Eur J Gastroenterol Hepatol. 2017 May 3. doi: 10.1097/MEG.0000000000000899.
    PubMed     Text format     Abstract available

  6. HERZOG D, Fournier N, Buehr P, Rueger V, et al
    Prevalence of intestinal complications in inflammatory bowel disease: a comparison between paediatric-onset and adult-onset patients.
    Eur J Gastroenterol Hepatol. 2017 May 3. doi: 10.1097/MEG.0000000000000896.
    PubMed     Text format     Abstract available

  7. DRAGASEVIC S, Stankovic B, Milosavljevic T, Sokic-Milutinovic A, et al
    Genetic and environmental factors significant for the presentation and development of inflammatory bowel disease.
    Eur J Gastroenterol Hepatol. 2017 Apr 27. doi: 10.1097/MEG.0000000000000877.
    PubMed     Text format     Abstract available


    Gastroenterology

  8. MAHADEVAN U
    How To Get an Education in Inflammatory Bowel Disease During Fellowship: Expectations and Realities.
    Gastroenterology. 2017 Apr 28. pii: S0016-5085(17)35540.
    PubMed     Text format    


    Inflamm Bowel Dis

  9. VAVRICKA SR, Gubler M, Gantenbein C, Spoerri M, et al
    Anti-TNF Treatment for Extraintestinal Manifestations of Inflammatory Bowel Disease in the Swiss IBD Cohort Study.
    Inflamm Bowel Dis. 2017 Apr 27. doi: 10.1097/MIB.0000000000001109.
    PubMed     Text format     Abstract available


    J Clin Gastroenterol

  10. CLICK B, Anderson AM, Ramos Rivers C, Koutroubakis IE, et al
    Telephone Encounters Predict Future High Financial Expenditures in Inflammatory Bowel Disease Patients: A 3-Year Prospective Observational Study.
    J Clin Gastroenterol. 2017 Apr 27. doi: 10.1097/MCG.0000000000000801.
    PubMed     Text format     Abstract available


    J Crohns Colitis

  11. HOVDE O, Hoivik ML, Henriksen M, Solberg IC, et al
    Malignancies in Patients with Inflammatory Bowel Disease: Results from 20 Years of Follow-up in the IBSEN Study.
    J Crohns Colitis. 2017;11:571-577.
    PubMed     Text format     Abstract available

  12. BEQUET E, Sarter H, Fumery M, Vasseur F, et al
    Incidence and Phenotype at Diagnosis of Very-early-onset Compared with Later-onset Paediatric Inflammatory Bowel Disease: A Population-based Study [1988-2011].
    J Crohns Colitis. 2017;11:519-526.
    PubMed     Text format     Abstract available

  13. DAPERNO M, Comberlato M, Bossa F, Armuzzi A, et al
    Training Programs on Endoscopic Scoring Systems for Inflammatory Bowel Disease Lead to a Significant Increase in Interobserver Agreement Among Community Gastroenterologists.
    J Crohns Colitis. 2017;11:556-561.
    PubMed     Text format     Abstract available

  14. EBERHARDSON M, Karlen P, Linton L, Jones P, et al
    Randomised, Double-blind, Placebo-controlled Trial of CCR9-targeted Leukapheresis Treatment of Ulcerative Colitis Patients.
    J Crohns Colitis. 2017;11:534-542.
    PubMed     Text format     Abstract available

  15. KARREMAN MC, Luime JJ, Hazes JMW, Weel AEAM, et al
    The Prevalence and Incidence of Axial and Peripheral Spondyloarthritis in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.
    J Crohns Colitis. 2017;11:631-642.
    PubMed     Text format     Abstract available

  16. MELESSE DY, Lix LM, Nugent Z, Targownik LE, et al
    Estimates of Disease Course in Inflammatory Bowel Disease Using Administrative Data: A Population-level Study.
    J Crohns Colitis. 2017;11:562-570.
    PubMed     Text format     Abstract available

  17. LIGHTNER AL, Loftus EV
    Response to 'Preoperative Vedolizumab and Postoperative Outcomes in Inflammatory Bowel Disease: Does Smoke Always Mean Fire?'
    J Crohns Colitis. 2017;11:644-645.
    PubMed     Text format    

  18. LIM KJ, Lee SJ, Kim S, Lee SY, et al
    Comparable Immune Function Inhibition by the Infliximab Biosimilar CT-P13: Implications for Treatment of Inflammatory Bowel Disease.
    J Crohns Colitis. 2017;11:593-602.
    PubMed     Text format     Abstract available

  19. CHU TPC, Moran GW, Card TR
    The Pattern of Underlying Cause of Death in Patients with Inflammatory Bowel Disease in England: A Record Linkage Study.
    J Crohns Colitis. 2017;11:578-585.
    PubMed     Text format     Abstract available

  20. LAMB CA, Mansfield JC, Tew GW, Gibbons D, et al
    alphaEbeta7 Integrin Identifies Subsets of Pro-Inflammatory Colonic CD4+ T Lymphocytes in Ulcerative Colitis.
    J Crohns Colitis. 2017;11:610-620.
    PubMed     Text format     Abstract available

  21. KOTZE PG, Yamamoto T
    Preoperative Vedolizumab and Postoperative Outcomes in Inflammatory Bowel Disease: Does Smoke Always Mean Fire?
    J Crohns Colitis. 2017;11:643.
    PubMed     Text format    

  22. MACMANUS CF, Collins CB, Nguyen TT, Alfano RW, et al
    VEN-120, a recombinant human lactoferrin, promotes a regulatory T cell (Treg) phenotype and drives resolution of inflammation in distinct murine models of inflammatory bowel disease.
    J Crohns Colitis. 2017 May 2. doi: 10.1093.
    PubMed     Text format     Abstract available

  23. TURNER D, Yerushalmi B, Kori M, Broide E, et al
    Once- Versus Twice-daily Mesalazine to Induce Remission in Paediatric Ulcerative Colitis: A Randomised Controlled Trial.
    J Crohns Colitis. 2017;11:527-533.
    PubMed     Text format     Abstract available


    J Immunol

  24. WANG H, Zhang X, Zuo Z, Zhang Q, et al
    Rip2 Is Required for Nod2-Mediated Lysozyme Sorting in Paneth Cells.
    J Immunol. 2017;198:3729-3736.
    PubMed     Text format     Abstract available


    N Engl J Med

  25. SANDBORN WJ, Su C, Sands BE, D'Haens GR, et al
    Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis.
    N Engl J Med. 2017;376:1723-1736.
    PubMed     Text format     Abstract available

  26. FRIEDMAN S
    Tofacitinib for Ulcerative Colitis - A Promising Step Forward.
    N Engl J Med. 2017;376:1792-1793.
    PubMed     Text format    


    Scand J Gastroenterol

  27. HOLT DQ, Strauss BJ, Lau KK, Moore GT, et al
    Body composition analysis using abdominal scans from routine clinical care in patients with Crohn's Disease.
    Scand J Gastroenterol. 2016;51:842-7.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Inflammatory Bowel Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: